Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGSC 20% in primary immunodeficiency diseases
2010-019459-23Phase 2Completed
- Sponsor
- Baxter International Inc.
- Start
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of IgPro20 in Immunogenetic disorder (2 arms), sponsored by Baxter International Inc. Primary endpoint: Acute serious bacterial infection rate. Started Jul 2010; status: completed.
02
Drugs
IgPro20
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2010-019459-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019459-23.